# US 6,726,909 B2 · Methods and compositions for treatment of autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,909 B2
- Document ID: US6726909B2
- Status: Granted
- Kind: B2
- Application number: 09/827,117
- Filed: 2001-04-05
- Published: 2001-10-18
- Granted: 2004-04-27
- Earliest claimed: 1996-12-11
- Assignees: University of Florida Research Foundation, Inc.
- Inventors: Ralph Williams
- Web page: https://patentgrep.com/patent/US6726909B2

## CPC

- C07K 16/42: against immunoglobulins
- C07K 16/4208: {against an idiotypic determinant on Ig}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- Y10S 530/866: involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
- Y10S 530/868: involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The subject invention concerns a method for therapeutically treating a patient afflicted with autoimmune disorders or disease. The subject method comprises administering to a patient an antibody composition that is capable of binding to and inhibiting self-reactive pathogenic antibodies present within the patient. Specifically exemplified is a method for treating systemic lupus erythematosis wherein the antibody composition administered to the patient comprises purified anti-DNA anti-idiotypic antibodies. The subject invention further concerns a method for purifying from pooled human gamma globulin preparations anti-idiotype antibodies useful in the present therapeutic method. The present invention further concerns a purified antibody composition useful in the present therapeutic method.

## Claims

### Claim 1

A method for treating a patient suffering from an autoimmune disorder said method comprising administering an effective amount of an antibody composition, wherein said antibody composition comprises anti-idiotype antibodies, or antigen binding fragments thereof, which can bind to and inhibit self reactive pathogenic autoantibodies present in the patient, and wherein said antibody composition is immunoreactive with idiotypes F4, 3I, 8.12, and 16/6 anti-DNA antibody determinants,
wherein said autoimmune disorder is symptomized by the destruction of patients' cells by autoantibodies, and
wherein said anti-idiotype antibodies are immunoreactive with idiotypic determinants present or antibodies associated with systemic lupus erythematosus.

### Claim 2 (depends on 1)

The method, according to claim 1, wherein said antibody composition is administered intravenously.

### Claim 3 (depends on 2)

The method, according to claim 2, wherein said antibody composition is administered as a dextrose saline solution.
